Xiao Kaimin, He Rongxin, Chen Hongmei, Liu Ping, Wu Jiao, Zhong Cai, Zhong Liang, Chu Heling, Tang Yuping, Chen Li, Lan Yu
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Neurology, People's Hospital of Ganxian District, Ganzhou, China.
Langenbecks Arch Surg. 2025 Jun 11;410(1):186. doi: 10.1007/s00423-025-03773-x.
Treatment options for intracranial atherosclerotic stenosis (ICAS) are limited, but endovascular intervention has gained increasing attention in recent years.
To evaluate the safety and efficacy of the Neuroform EZ stent for treating ICAS in the posterior circulation.
MATERIAL & METHODS: Patients' (n = 50) eligibility depended on ICAS with severe stenosis (≥ 70%) in the intracranial segment of the vertebral artery or basilar artery shown by cerebral angiography. General information of the participants were recorded, Adverse events during the perioperative period were observed, including in-stent thrombosis, postoperative hyperperfusion, stroke, and mortality. Before the procedure, neurological deficits (NIHSS score) and neurological recovery (mRS score) were recorded at 12 months postoperatively. The degree of vascular stenosis was evaluated prior to and following the procedure, and in-stent restenosis (ISR) was recorded at 12 months post-operation.
Fifty-two stents were successfully placed in 50 patients, followed by standardized medication. Angiographic follow-up was completed 12-months postoperatively, and there was only one case of ISR (4.35%) was observed. Postoperative stenosis of responsible vessel was significantly relieved (77.98 ± 7.69 vs. 33.85 ± 9.11), with statistically significant differences (P < 0.01). The extent of neurological deficits and effects on daily living activities at 12 months postoperatively exhibited significant improvements, as evidenced by NIHSS scores (2.40 ± 1.37 vs. 0.82 ± 0.77) and mRS scores ≤ 2 (82.0% vs. 98.0%) (P < 0.01). Cerebral perfusion improved, with no significant perioperative complications.
The Neuroform EZ stent is a safe and effective treatment approach for ICAS in the posterior circulation.
颅内动脉粥样硬化性狭窄（ICAS）的治疗选择有限，但近年来血管内介入治疗越来越受到关注。
评估Neuroform EZ支架治疗后循环ICAS的安全性和有效性。
50例患者的入选标准为经脑血管造影显示椎动脉或基底动脉颅内段存在严重狭窄（≥70%）的ICAS。记录参与者的一般信息，观察围手术期不良事件，包括支架内血栓形成、术后高灌注、中风和死亡率。术前记录神经功能缺损（NIHSS评分），术后12个月记录神经功能恢复情况（mRS评分）。在手术前后评估血管狭窄程度，并在术后12个月记录支架内再狭窄（ISR）情况。
50例患者成功植入52枚支架，随后进行标准化药物治疗。术后12个月完成血管造影随访，仅观察到1例ISR（4.35%）。责任血管术后狭窄明显缓解（77.98±7.69 vs. 33.85±9.11），差异有统计学意义（P<0.01）。术后12个月神经功能缺损程度和对日常生活活动的影响有显著改善，NIHSS评分（2.40±1.37 vs. 0.82±0.77）和mRS评分≤2（82.0% vs. 98.0%）证明了这一点（P<0.01）。脑灌注改善，围手术期无明显并发症。
Neuroform EZ支架是治疗后循环ICAS的一种安全有效的治疗方法。
